Itziar Cenzano, PhD1*, Miguel Cocera1*, Robert Lehmann, PhD2*, Jin Ye2*, Amaia Vilas-Zornoza1*, Patxi San-Martin1*, Paula Aguirre-Ruiz3*, Diego Alignani1*, Aitziber Lopez1*, Bruno Paiva1*, Marta Miñana Barrios, MD4*, Ignacio Sancho Gonzalez, MD5*, Javier Ruiz, MD5*, Sarai Sarvide1*, Purificacion Ripalda-Cemborain3*, Laura Sudupe2*, Emma Muiños-Lopez, PhD1*, Vincenzo Lagani, PhD2*, Jesper Tegner, PhD2*, Borja Saez-Ochoa, PhD3*, Isabel A Calvo, PhD3*, David Gomez-Cabrero, PhD2,6* and Felipe Prosper, MD, PhD7,8,9
1Hematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain
2Bioscience Program, Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology KAUST, Thuwal, Saudi Arabia
3Hematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain, Pamplona, Spain
4Hospital Reina Sofía de Tudela, Tudela, Spain
5Hospital Universitario de Navarra, Pamplona, Spain
6Translational Bioinformatics Unit, Navarrabiomed, Universidad Pública de Navarra (UPNA), Pamplona, Spain
7Centro de Investigacion Biomedica en Red de Cancer (CIBERONC)., Madrid, Spain
8Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain
9Hematology and Cell Therapy Department. Clinica Universidad de Navarra, IdiSNA., Pamplona, Spain